Detailed view for Tb927.10.5260
Basic information
Trypanosoma brucei, C2 domain containing protein, putative
Source Database / ID: TriTrypDB GeneDB
pI: 7.6208 |
Length (AA): 1135 |
MW (Da): 125065 |
Paralog Number:
2
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Network
Pfam domains
Gene Ontology
Metabolic Pathways
Structural information
Modbase 3D models:
PDB Structures:
Expression
| Upregulation Percent | Ranking | Stage | Dataset |
|---|---|---|---|
| Lower 20-40% percentile | Procyclic, Bloodstream Form. | Siegel TN |
-
Siegel TN Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites.
Orthologs
Ortholog group members (OG5_167681)
| Species | Accession | Gene Product |
|---|---|---|
| Trypanosoma brucei gambiense | Tbg972.10.6420 | hypothetical protein, conserved |
| Trypanosoma brucei | Tb927.10.5260 | C2 domain containing protein, putative |
| Trypanosoma brucei | Tb11.v5.0497 | hypothetical protein, conserved |
| Trypanosoma brucei | Tb11.v5.0250 | C2 domain containing protein, putative |
| Trypanosoma congolense | TcIL3000_10_4400 | C2 domain containing protein, putative |
| Trypanosoma cruzi | TcCLB.506679.30 | C2 domain containing protein, putative |
Essentiality
| Gene/Ortholog | Organism | Phenotype | Source Study |
|---|---|---|---|
| Tb927.10.5260 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
| Tb927.10.5260 this record | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
| Tb927.10.5260 this record | Trypanosoma brucei | significant gain of fitness in procyclic forms | alsford |
| Tb927.10.5260 this record | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
-
yeastgenome Systematic deletion of yeast genes Saccharomyces Genome Database -
shigen Profiling of E. coli Chromosome (PEC) National Institute of Genetics, Japan -
nmpdr Genome-scale essentiality datasets from published studies (M. tuberculosis) National Microbial Pathogen Data Resource -
gerdes Experimental determination and system-level analysis of essential genes in E. coli MG1655 Gerdes et al., J Bacteriol. 2003 185:5673-84 -
alsford High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome Genome Res 2011, 21:915-924 -
keio Systematic single-gene knock-out mutants of E. coli K12 The Keio Collection -
neb C. elegans RNAi phenotypes Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs -
blattner Systematic mutagenesis of the E. coli (MG1655) genome J Bacteriol 2004, 186:4921-4930 -
wormbase C. elegans RNAi experiments WormBase web site, http://www.wormbase.org, release WS170
Phenotypes and Validation (curated)
Annotated phenotypes:
| Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
|---|---|---|---|---|---|---|
| cell proliferation (GO:0008283) | normal (PATO:0000461) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
| Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in bloodstream forms (stage 3 days). | References: | 21363968 | |
| cell proliferation (GO:0008283) | decreased (PATO:0000468) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
| Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
| cell proliferation (GO:0008283) | increased (PATO:0000470) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
| Annotator: | fernan@iib.unsam.edu.ar. | Comment: | increased cell proliferation (significant gain of fitness) in procyclic forms . | References: | 21363968 | |
| cell proliferation (GO:0008283) | decreased (PATO:0000468) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
| Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 | |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Annotated validation
Associated compounds / Druggability
Known modulators for this target
Predicted associations
By orthology with druggable targets
By sequence similarity to non orthologous druggable targets
Obtained from network model
Assayability
Assay information
Reagent availability
Bibliographic References
1 literature reference was collected for this gene.